Philadelphia, US, and Nottingham, UK, 27th June 2017: QS Pharma, the Contract Development and Manufacturing Organisation (CDMO), which was acquired by Quotient Clinical (“Quotient”) in February 2017, today announced it has received approval from the European Medicines Agency (EMA) to manufacture certain medicinal products for commercial use  in Europe.

QS Pharma’s manufacturing facility in Boothwyn, Pennsylvania was inspected in February 2017 by the Dutch Health Care Inspectorate (IGZ) at the request of the EMA. The assessment focused on two NDA filed products, and the overall quality systems of QS Pharma. Following the successful outcome of the inspection, added to past approvals from the FDA and PDMA, QS Pharma is now approved to manufacture medicinal products for the US, Europe and Japan.

Nutan Gangrade, Managing Director, QS Pharma, said: “QS Pharma is dedicated to maintaining a robust quality system, underpinned by our excellent  regulatory history. This approval by the EMA ensures we are able to support customers with interests in Europe, creating further growth opportunities for the business.”

Mark Egerton, Chief Executive Officer, Quotient Clinical, said: “QS Pharma is becoming a major global player in the commercial manufacture of market products, with a focus on high potency manufacturing, and niche therapies and markets such as orphan drugs, for tablets, capsules and oral liquids. This latest inspection and approval adds further value to the business.”

To find out more about QS Pharma, please click here.

To find out more about Quotient Clinical, please click here.

Latest Opportunities

Study brief: The effects of a recovery gel on endurance cycling performance in the heat

The popularity of endurance sports like cycling and running has grown significantly over the past…

UKRI unveils new £9 million proof-of-concept fund

The UKRI Proof of Concept funding opportunity aims to support and accelerate the development of…

Peer advice on “demand forecasting strategies”

An established Midlands-based health manufacturer is keen to hear from others about their demand forecasting…

Latest News

Illuminating biology: Advanced imaging and computational techniques transforming medical research at the University of Warwick

Advances in imaging and computational techniques are enabling researchers to discover more than ever before…

From firefighting to future-proofing: Why predictive compliance is key in medical device software

By Medilink Midlands Member Coauthor by Hindsight In today’s fast-paced and highly regulated world of…

IMed Consultancy new whitepaper reveals how to transform gruelling PMS procedures into commercial benefit

IMed Consultancy’s new free whitepaper, “PMS from pain to potential: more than just ticking a…